Sepracor Inc. is a fully integrated, research-based specialty pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs.
More >>

2010 | 2009 | 2008                                                     DSPA 2009 Press Releases

Date	Title
07/15/10	Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.
06/30/10	Sepracor Reports Preliminary Results from a Second Phase III Study for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis
05/03/10	FDA Provides Complete Response to Sepracor's New Drug Application For STEDESA™
03/10/10	Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
02/19/10	Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
01/27/10	FDA Extends PDUFA Action Date for STEDESA™ New Drug Application
01/04/10	Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia